KyungDong Pharm home
Prescription Medicines

Telcardin Tab. 80mg

Product Category
ARB antihypertensive drugs
Active Ingredients
Telmisartan
Appearance
A white, oval tablet.
Reimbursement Code
648105160
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength : 1 tablet (480.0 mg) of this medicine
- Active ingredients:
Telmisartan (EP) · · · · · · · · 80.0mg
- Additives: Magnesium metasilicate aluminate, anhydrous calcium hydrogen phosphate, microcrystalline cellulose, sodium hydroxide, sodium stearyl fumarate, low-substituted hydroxypropyl cellulose, calcium carboxymethyl cellulose, colloidal silicon oxide, crospovidone, hypromellose, D-mannitol.

2. Effectiveness
1. Essential hypertension
2. Reduces the risk of cardiovascular disease
Reduces the risk of myocardial infarction, stroke, and death from cardiovascular disease in patients over 55 years of age who cannot tolerate ACE inhibitors and are at high risk of developing major cardiovascular disease (high-risk diabetic patients with a past history of coronary artery disease, peripheral artery disease, stroke, transient ischemic attack, or clinical evidence of end-organ damage)

3. Dosage and dosage
1. Essential hypertension
Adults: Telmisartan should be administered orally at 40 mg once a day with water, and can be taken with or without food. Depending on the patient, 20 mg once a day may be effective. If necessary, the dose can be increased to 80 mg once a day. When increasing the dose, the maximum blood pressure lowering effect occurs 4 to 8 weeks after starting treatment.
This drug has an additional blood pressure lowering effect when administered in combination with thiazide diuretics such as hydrochlorothiazide.
2. Reduces the risk of cardiovascular disease
Adults: It is recommended to take this drug orally, 80 mg once a day with water, and can be taken with or without food. There is no known risk-reducing effect on cardiovascular morbidity and mortality at doses less than 80 mg. When initiating treatment with this drug for the purpose of reducing the risk of cardiovascular disease, monitoring blood pressure is recommended and appropriate adjustment of antihypertensive medications may be required.
○ Patients with liver impairment
It should be administered with caution to patients with mild to moderate hepatic impairment and should not exceed 40 mg once a day.

4. Precautions for use
1. Warning
When drugs that act directly on the renin-angiotensin-aldosterone system (RAAS) are administered to pregnant women, damage and even death may occur in the fetus and newborn. Dozens of such cases have been reported worldwide, even in patients taking ACE inhibitors. Therefore, if pregnancy is confirmed, administration of this drug should be discontinued immediately (see ‘Administration to pregnant and lactating women’ section).

2. Do not administer to the following patients.
1) Patients with hypersensitivity to this drug or its components
2) Pregnant women, women who may be pregnant, and lactating women
3) Patients with severe hepatic impairment, biliary obstruction, or cholestasis (This drug is almost always excreted through bile. A decrease in liver clearance can be expected in patients with cholestasis, biliary obstructive disease, or hepatic impairment.)
4) Patients with hereditary angioedema or a history of angioedema during treatment with ACE inhibitors or angiotensin II receptor antagonists
5) Combination use with aliskiren-containing preparations in patients with diabetes or moderate to severe renal impairment (glomerular filtration rate <60mL/min/1.73m2)

3. Administer with caution to the following patients.
1) Elderly people
2) Patients with hyperkalemia or patients prone to elevated serum potassium levels
3) Patients with mild to moderate hepatic impairment (should be administered with caution and should not exceed 40 mg once a day)
4) Patients with aortic and mitral valve stenosis or obstructive hypertrophic cardiomyopathy
5) Patients with ischemic heart disease, ischemic cardiovascular disease, and cerebrovascular disorder (excessive drop in blood pressure can cause myocardial infarction or stroke due to cerebral blood flow failure.)
6) Patients with gastrointestinal diseases such as active stomach or duodenal ulcer
7) Patients with renal vascular hypertension (patients with bilateral renal artery stenosis or renal artery stenosis of a single functioning kidney)
8) Patients with severe renal impairment (administer cautiously if serum creatinine is 3.0 mg/dL or higher as there is a risk of worsening renal function.)
9) Dual blockade of the renin-angiotensin-aldosterone system (RAAS): Concurrent use with other drugs that affect the renin-angiotensin-aldosterone system (RAAS), such as angiotensin II receptor antagonists (ARBs), ACE inhibitors, or aliskiren, is not recommended (see section 2.5).

4. Adverse reactions
1) In a placebo-controlled clinical trial conducted on patients with hypertension, the overall frequency of adverse reactions reported after telmisartan administration was similar to that of placebo: 41.4% in the telmisartan group and 43.9% in the placebo group. The incidence of these adverse reactions is not related to the dose and is also independent of the patient's gender, age, or race.
The safety profile of telmisartan obtained in patients who received this drug to evaluate the effect of reducing the risk of cardiovascular disease was identical to that obtained in clinical trials conducted on patients with hypertension.
The list of adverse reactions below was compiled from controlled clinical trials and post-marketing surveillance conducted in patients with hypertension. Additionally, the following table considers serious adverse events and adverse events that required discontinuation of the clinical trials reported in three long-term clinical trials of up to 6 years (including 21,642 patients receiving telmisartan to evaluate cardiovascular disease risk reduction).
The frequency of occurrence of adverse reactions is defined as follows. : Uncommon (≥ 1/1,000, < 1/100); Rare (≥ 1/10,000, < 1/1,000); Very rare (< 1/10,000)
Within each frequency category, adverse reactions were described in descending order of severity.
※ Table: Refer to attached document

2) Metabolic abnormalities: Since there are rare cases of hypoglycemia (this is likely to occur in patients receiving diabetes treatment), sufficient observation should be conducted. If helplessness, hunger, cold sweat, hand tremors, decreased concentration, convulsions, or impaired consciousness appear, administration should be stopped and appropriate measures should be taken.
3) Angioedema: There have been reported cases of angioedema, which is characterized by swelling of the face, lips, pharynx, larynx, tongue, etc., resulting in breathing difficulties due to laryngeal edema. Therefore, sufficient observation is conducted, and if abnormalities are recognized, administration should be stopped immediately and appropriate measures should be taken.
4) Hyperkalemia: Severe hyperkalemia may occur, so observe thoroughly and take appropriate measures immediately if abnormalities are recognized.
5) Renal dysfunction: Cases of renal failure have been reported, so sufficient observation is conducted, and if abnormalities are recognized, appropriate measures, such as discontinuation of administration, are taken.
6) Shock, fainting, loss of consciousness: Shock, fainting, and loss of consciousness due to a drop in blood pressure may occur, so observe thoroughly and take appropriate measures immediately if a cold feeling, vomiting, loss of consciousness, etc. appears. In particular, patients undergoing hemodialysis, strict salt restriction, or diuretics should start treatment at a low dose and increase the dose slowly while carefully observing the patient's condition.
7) Liver dysfunction, jaundice: Liver dysfunction and jaundice, such as elevations in AST, ALT, ALP, and LDH, may occur. Observe thoroughly, and if abnormalities are recognized, take appropriate measures, such as discontinuing administration.
8) Anaphylaxis-like symptoms: Difficulty breathing, lowered blood pressure, laryngeal edema, etc. may appear as symptoms, so observe sufficiently and if abnormalities are recognized, stop administration and take appropriate measures.
9) Interstitial pneumonia (frequency unknown): Interstitial pneumonia accompanied by fever, cough, difficulty breathing, and chest X-ray abnormalities may occur. In such cases, discontinue administration and take appropriate measures, such as administration of corticosteroids.
10) Rhabdomyolysis (frequency unknown): Rhabdomyolysis, which is characterized by muscle pain, weakness, elevation of creatine kinase (CK), and elevation of myoglobin in blood and urine, may occur, so observe thoroughly, and in such cases, stop administration and take appropriate measures.
11) In addition to the adverse reactions mentioned above, palpitations, fatigue, nausea, and lack of effect have been reported.
12) As a result of a large-scale post-marketing use survey conducted on 15,601 hypertensive patients in Korea, the adverse reaction rate was 1.54% (240 cases/15,601 cases), of which a causal relationship with the drug could not be ruled out in 1.2% (183 cases/15,601 cases). Headache was the most common at 0.38% (60 cases/15,601 cases), followed by dizziness at 0.2% (33 cases/15,601 cases), cough at 0.13% (21 cases/15,601 cases), indigestion at 0.07% (11 cases/15,601 cases), and palpitations at 0.06%. The order was % (10 cases/15,601 cases). One case of arrhythmia was reported as a serious adverse reaction.
A causal relationship with the drug cannot be ruled out, and new adverse reactions that had a lower incidence rate than placebo in pre-marketing clinical trials (marked with *) or that did not appear in pre-marketing clinical trials are as follows (numbers in parentheses indicate occurrence rates).
(1) Central and peripheral nervous system: headache* (60), facial convulsions (2), paresthesia (2), paralysis (1),
(2) Respiratory system: cough* (21), hyperventilation (1), pneumonia (1)
(3) Autonomic nervous system: flushing (5), erectile dysfunction (1), anorexia (1), arrhythmia (1)
(4) Whole body: Asthenia (4), edema (3)
(5) Mental nervous system: decreased sexual desire (2)
(6) Skin and appendages: facial edema (1), rash (1), alopecia (1)
(7) Sense organs: conjunctivitis (1), sound in the ears (1)
(8) Platelet bleeding and coagulation abnormalities: petechiae (1)
Among these, the adverse reaction rate in patients with renal impairment was 0.9% (4 cases/445 cases), with headache, dizziness, muscle pain, and dermatitis reported, and the adverse reaction rate in patients with liver impairment was 2.0% (6 cases/296 cases), with dizziness, indigestion, cough, abdominal pain, loss of appetite, and asthenia reported.

5. General precautions
1) Patients with renal impairment and kidney transplant
When administering this drug to patients with renal impairment, periodic monitoring of serum potassium and creatinine levels is recommended. There is no experience with the use of this drug in patients who recently underwent kidney transplantation. This drug does not require dosage adjustment in patients with renal impairment, including those receiving hemodialysis, and is not eliminated by hemofiltration or dialysis.
2) Patients with decreased blood volume and/or sodium
Patients with blood volume and/or sodium depletion due to high doses of diuretics, dietary salt restriction, diarrhea and vomiting, or patients on hemodialysis may experience symptoms of hypotension, especially after the first dose. These symptoms, especially blood volume and/or sodium depletion, should be corrected prior to administration of this drug. If low blood pressure occurs, place the patient supine and inject intravenous saline solution if necessary.
3) Other conditions that stimulate the renin-angiotensin-aldosterone system
In patients whose vascular tone and renal function depend primarily on the activity of the renin–angiotensin–aldosterone system, such as those with severe congestive heart failure or underlying renal disease including renal artery stenosis, treatment with other medicines that affect this system has been associated with acute hypotension, azotemia, urinary frequency and, rarely, acute renal failure and/or death. Similar outcomes may be expected in patients receiving this medicine.
4) Electrolyte imbalance/hyperkalemia
Taking drugs that affect the renin-angiotensin-aldosterone system may cause hyperkalemia. Hyperkalemia can be fatal in the elderly, patients with renal failure, patients with diabetes, and patients taking medications that can affect serum potassium levels. The benefits and risks should be considered before concurrent use of drugs that affect the renin-angiotensin-aldosterone system. The main risk factors that can cause hyperkalemia are:
- Diabetes, heart failure, kidney failure, elderly people (> 70)
- Drugs that affect the renin-angiotensin-aldosterone system (potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium, and other drugs that can increase potassium levels (such as heparin)), ACE inhibitors, angiotensin II receptor antagonists, non-steroidal anti-inflammatory drugs (NSAIDs including selective COX-2 inhibitors), When taking one or more immunosuppressants (cyclosporine, tacrolimus), trimethoprim, etc. in combination.
- In case of concurrent diseases such as dehydration, acute loss of cardiac compensation mechanism, metabolic acidosis, worsening of renal function, sudden worsening of renal condition (e.g., infectious disease), cell lysis (e.g., acute limb ischemia, rhabdomyolysis, extended trauma)
5) It is advisable not to administer 24 hours before surgery.
6) In patients with gastrointestinal diseases such as active stomach or duodenal ulcer, gastrointestinal adverse reactions occurred more frequently when taking this drug than when taking placebo. Gastrointestinal bleeding has been rarely observed in clinical trials, mostly occurring early in patients with gastrointestinal diseases. Therefore, caution should be exercised when administering this drug to patients with gastrointestinal diseases.
7) When patients with renovascular hypertension (bilateral renal artery stenosis or renal artery stenosis of a single functioning kidney) are treated with drugs that affect the renin-angiotensin-aldosterone system, the risk of severe hypotension or renal failure increases. When this drug is administered to patients with bilateral or unilateral renal artery stenosis, an increase in serum creatinine or blood uric acid nitrogen is expected, similar to ACE inhibitors. Additionally, because there is a risk of rapidly deteriorating renal function due to decreased renal blood flow and glomerular filtration pressure, it is recommended to avoid use except in cases where treatment is deemed unavoidable.
8) In general, patients with primary aldosteronism are not responsive to antihypertensive drugs that inhibit the renin-angiotensin-aldosterone system, so administration of this drug is not recommended for these patients.
9) Effects on driving and operating machinery: Although no studies have been conducted on the effects of this drug on driving and operating machinery, when taking antihypertensive drugs, fainting and vertigo may sometimes occur, so patients taking this drug should be careful when driving a car or operating dangerous machinery.
10) This drug contains sorbitol, so it is not suitable for patients with genetic fructose intolerance (limited to sorbitol-containing drugs).
11) In diabetic patients at additional risk for cardiovascular disease (e.g., patients with diabetes and coronary artery disease), the risk of fatal myocardial infarction and unexpected death from cardiovascular disease may increase when taking antihypertensive agents such as angiotensin II receptor antagonists or ACE blockers. Since diabetic patients do not show symptoms of coronary artery disease and may not be diagnosed, an appropriate diagnostic evaluation for coronary artery disease (e.g., exercise stress test) should be performed first before administering this drug to diabetic patients.

6. Interaction
1) Dual blockade of the renin-angiotensin-aldosterone system (RAAS) by co-administration of angiotensin II receptor antagonists (ARBs), ACE inhibitors, or aliskiren is associated with an increased risk of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy with these drugs. In patients receiving this drug concomitantly with other drugs that act on RAAS, blood pressure, renal function, and electrolytes should be closely monitored. Do not administer this drug and aliskiren-containing preparations together in patients with diabetes or moderate to severe renal impairment (glomerular filtration rate <60 mL/min/1.73m2) (see Section 2.5).
2) This drug may increase the blood pressure lowering effect of other blood pressure lowering drugs.
3) No clinically significant interactions were observed with co-administration of this drug with warfarin, hydrochlorothiazide, glibenclamide, ibuprofen, acetaminophen, simvastatin, and amlodipine.
4) Digoxin: By co-administering digoxin and this drug, the median peak concentration of digoxin in plasma increased by 49%, and the median basal concentration increased by 20% (39% increase in 1 case). Therefore, monitoring of plasma digoxin levels is recommended in these cases.
5) Ramipril: As a result of the combined administration test of telmisartan and ramipril, the AUC0-24h value and the Cmax value of ramipril and ramipril rat increased by 2.5 times. When telmisartan and ramipril are coadministered, the effects may be enhanced due to pharmacodynamic additive effects and increased exposure of ramipril/ramiprilat. Co-administration of this drug and ramipril is not recommended.
6) Lithium: When ACE inhibitors and lithium are administered together, a reversible increase in serum lithium levels and toxicity have been reported. Angiotensin II receptor antagonists, including this drug, have also been reported to cause this toxicity. Therefore, careful monitoring of serum lithium levels is recommended during co-administration of this drug and lithium, and co-administration is generally not recommended.
7) This drug is not metabolized by the CYP-450 system and, except for some CYP2C19 inhibitors, has no effect on CYP-450 enzymes in vitro. Except for the potential for inhibition of the metabolism of drugs metabolized by CYP2C19, no interactions are expected between this drug and drugs metabolized by CYP-450 enzymes and drugs that inhibit CYP-450 enzymes.
8) Orthostatic hypotension may be worsened by baclofen, amifostine, alcohol, barbiturates, narcotics, and antidepressants.
9) Non-steroidal anti-inflammatory drugs (NSAIDs): When angiotensin II receptor antagonists are used in combination with NSAIDs (e.g., selective COX-2 inhibitors, acetylsalicylic acid (> 3 g/day), non-selective NSAIDs), the blood pressure lowering effect may be reduced. Like ACE inhibitors, combined use of angiotensin II receptor antagonists and NSAIDs can worsen renal function, cause acute renal failure, and increase serum potassium. Caution must be exercised when using together, especially in the elderly or patients with reduced effective blood volume (including patients receiving diuretic treatment). After starting combination treatment, patients should be provided with adequate fluids and renal function should be monitored periodically.
10) Potassium-sparing diuretics or potassium supplements: Angiotensin II receptor antagonists such as telmisartan weaken the diuretic effect due to loss of potassium. Potassium-sparing diuretics (spironolactone, eplerenone, triamterene, or amiloride), potassium supplements, or salt substitutes containing potassium may increase serum potassium levels. If this drug is co-administered due to hypokalemia, administer with caution while frequently monitoring serum potassium levels. In general, coadministration is not recommended.
11) Adrenocortical hormones (corticosteroids, systemic administration): When administered together with this drug, the blood pressure lowering effect may be reduced.
12) Diuretics (thiazides or loop diuretics): Before starting treatment with this drug, high-dose use of diuretics such as loop diuretics (furosemide) and thiazide diuretics (hydrochlorothiazide) may increase the risk of fluid depletion and hypotension.

7. Administration to pregnant and lactating women
1) Reproductive function: The effect of this drug on human reproductive function has not been studied. No effects of this drug on fertility were observed in nonclinical studies using male and female rats.
2) The use of angiotensin II receptor antagonists during the first trimester of pregnancy is not recommended, and medication should not be started during pregnancy. Because of the mechanism of action of angiotensin II receptor antagonists, the risk to the fetus cannot be ignored. In pregnant women exposed to ACE inhibitors (a specific group of drugs that act on the renin-angiotensin-aldosterone system) during the second or third trimester of pregnancy, they have been associated with fetal and neonatal damage, including fetal and neonatal hypotension, hyperkalemia, neonatal cranial hypoplasia, urinary retention and/or anuria, reversible or irreversible renal failure, intrauterine growth retardation, and death. Oligohydramnios, presumed to be due to decreased fetal renal function, has been reported, and oligohydramnios has been associated with fetal limb contractures, craniofacial malformations, and pulmonary hypoplasia. Retrospective data suggest that use of ACE inhibitors in the first trimester of pregnancy is associated with a potential risk of birth defects. Additionally, although it is not clear whether this drug is caused by it, there are reports of prematurity, intrauterine growth retardation, and patent ductus arteriosus. Like other drugs that act directly on the renin-angiotensin-aldosterone system, this drug should not be used by women who are pregnant or planning to become pregnant, and if pregnancy is confirmed while taking the drug, the drug should be discontinued immediately. When prescribing drugs that act on the renin-angiotensin-aldosterone system to women who may become pregnant, doctors should inform them of the potential risks of these drugs during pregnancy. If a pregnant woman has been exposed to angiotensin II receptor antagonists beyond the second trimester, fetal renal function and cranial ultrasound examination is recommended. Additionally, neonates who have been exposed to this drug in utero should be closely monitored for sufficient urination, hyperkalemia, and blood pressure.
3) It is not known whether this drug passes into breast milk, but secretion of this drug in milk was confirmed in experiments on rats, so it is not recommended for nursing mothers to use this drug. Avoid administering this drug to breastfeeding women, and if administration is unavoidable, breast-feeding should be discontinued.

8. Administration to children
The safety and effectiveness of this drug in children under 18 years of age have not been established, so administration of this drug is not recommended.

9. Administration to elderly people
It is generally said that excessive lowering of blood pressure is not desirable for elderly people (there is a risk of cerebral infarction, etc.). When administering to the elderly, administer carefully while observing the patient's condition.

10. Treatment in case of overdose
There is limited information available on overdose in humans.
The most notable symptoms of overdosage of this drug include hypotension, tachycardia, bradycardia (due to parasympathetic stimulation), dizziness, and acute renal failure. Treatment If symptoms of hypotension appear, supportive treatment should be administered. This drug is not removed by hemofiltration or dialysis. Patients should be carefully observed, and symptomatic and supportive treatment should be administered depending on the time elapsed after taking the drug and the severity of symptoms. Inducing vomiting may also be considered. Medicinal charcoal may be useful for treatment. Serum electrolyte levels and creatinine levels should be monitored frequently. If hypotension occurs, the patient should be laid down and salt and fluid substitutes should be quickly supplied.

11. Storage and handling precautions
1) Keep out of reach of children.
2) Be careful because changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
3) Considering the hygroscopicity of the tablet, open the sealed aluminum foil immediately before taking.

12. Pharmaceutical equivalence test information Note 1)
A. The test drug Myrto tablets 80 mg (telmisartan) (Withers Pharmaceutical Co., Ltd.) and the reference drug Micardis tablets 80 mg (telmisartan) (Korea Boehringer Ingelheim Co., Ltd.) were orally administered as a single dose on an empty stomach to healthy adults in a 2 When log transformed and subjected to statistical processing, the 90% confidence interval of the mean difference was within log 0.8 to log 1.25, proving biological equivalence.
※ Table: Refer to attached document
Note 1) This drug was manufactured by Withers Pharmaceutical Co., Ltd. using the same raw materials as Myrto Tablet 80 mg (telmisartan) and the entire process was manufactured by Withers Pharmaceutical Co., Ltd. using the same manufacturing method.

13. Others
As a result of non-clinical safety tests, when a dose corresponding to the clinical therapeutic dose was administered to animals with normal blood pressure, a decrease in erythrocyte parameters (e.g., erythrocytes, hemoglobin, hematocrit), renal hemodynamic changes (increased blood urea nitrogen and creatinine), and an increase in serum potassium were reported. In dogs, renal tubular dilatation and atrophy were observed. Additionally, gastrointestinal mucosal damage (erosions, ulcers, or inflammation) has been observed in rats and dogs. Adverse reactions resulting from pharmacological effects reported in non-clinical trial data of ACE inhibitors and angiotensin II receptor antagonists were prevented by oral administration of physiological saline.
In both animal species (rat and dog), increased plasma renin activity and hypertrophy and proliferation of renal juxtaglomerular cells were observed. These changes, like those reported with ACE inhibitors and other angiotensin II receptor antagonists, are not clinically significant.
Although there is no evidence of teratogenicity, animal experiments have reported potential risks of telmisartan in postnatal development in subsequent generations, such as weight loss, delayed eye opening, and increased mortality. There is no evidence of genotoxicity or chromosomal mutagenicity in in vitro studies, and no evidence of carcinogenicity in rats and mice.

5. How to save
Airtight container, stored at room temperature (1~30℃)

6. Packaging unit
30 tablets/Alu-Alu (30 tablets/box (10 tablets/Alu-Alu x 3)), 30 tablets/bottle

7. Period of use
36 months from date of manufacture

Product Updates

Total 1items

No.Product NameDetailsDate of ChangeDownload
1Telcardin Tab. 80mgPrecautions for use2026.02.12PDF0251_201801391_Precautions for use_Telcadin tablet 80mg.pdf